SEPN Septerna, Inc.
Septerna, Inc. (SEPN) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 7% planned / 93% discretionary
Largest single sale: $31.7M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Long Daniel D. | SVP, Drug Discovery | Sell 10b5-1 | 3,333 | $37.83 | $126.1K | 96,412 −3.3% of holding | |
| 2 fills | Sell | 1,493,000 | $42.50 | $63.5M | 4,777,415 −23.8% of holding | ||
| Bhatt Elizabeth | President and COO | Sell 10b5-1 | 25,000 | $44.00 | $1.1M | 174,209 −12.5% of holding | |
| Long Daniel D. 2 fills | SVP, Drug Discovery | Sell 10b5-1 | 3,334 | $34.47 | $114.9K | 98,746 −3.3% of holding | |
| Bhatt Elizabeth | President and COO | Sell 10b5-1 | 4,000 | $33.99 | $136.0K | 174,209 −2.2% of holding | |
| Long Daniel D. 2 fills | SVP, Drug Discovery | Sell 10b5-1 | 3,333 | $34.36 | $114.5K | 97,645 −3.3% of holding | |
| Shaikhly Samira | Chief People Officer | Sell 10b5-1 | 2,178 | $35.18 | $76.6K | 793 −73.3% of holding | |
| Long Daniel D. 2 fills | SVP, Drug Discovery | Sell 10b5-1 | 15,000 | $35.51 | $532.6K | 103,412 −12.7% of holding | |
| Shaikhly Samira | Chief People Officer | Sell 10b5-1 | 6,250 | $35.08 | $219.2K | 793 −88.7% of holding | |
| Shaikhly Samira 3 fills | Chief People Officer | Sell 10b5-1 | 5,935 | $28.93 | $171.7K | 5,028 −54.1% of holding | |
| Shaikhly Samira | Chief People Officer | Sell 10b5-1 | 11,798 | $30.06 | $354.7K | 793 −93.7% of holding | |
| Bhatt Elizabeth 3 fills | President and COO | Sell 10b5-1 | 4,000 | $24.34 | $97.3K | 175,636 −2.2% of holding | |
| Shaikhly Samira 2 fills | Chief People Officer | Sell 10b5-1 | 70,453 | $28.10 | $2.0M | 67,156 −51.2% of holding | |
| Bhatt Elizabeth 2 fills | President and COO | Sell 10b5-1 | 4,000 | $28.97 | $115.9K | 176,009 −2.2% of holding | |
| Long Daniel D. | SVP, Drug Discovery | Sell | 3,501 | $18.06 | $63.2K | 92,911 −3.6% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.